{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/trichomoniasis/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"4c83875e-ed21-58f7-99f4-4a509deb53b5","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field 73a708f9-98c6-46b6-a3df-793a27bc64e0 --><h2>Metronidazole</h2><!-- end field 73a708f9-98c6-46b6-a3df-793a27bc64e0 -->","summary":"","htmlStringContent":"<!-- begin item 8e64caa1-d6c0-4e8c-93f9-b0a7a3c1a087 --><!-- end item 8e64caa1-d6c0-4e8c-93f9-b0a7a3c1a087 -->","topic":{"id":"3fa4323b-9014-5631-9410-a93ec7d2d0ac","topicId":"97ea63d1-8933-4fee-b1dd-7c6ac3ea2ab7","topicName":"Trichomoniasis","slug":"trichomoniasis","lastRevised":"Last revised in May 2020","chapters":[{"id":"e42d9436-b807-5262-a262-948244b520b5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2b56e4dc-02e3-599e-a6bf-1a5413d868f0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"46f9586c-8974-558f-8ac1-6244bfd1883b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"65ddd7d3-15b0-53be-866f-5610e15e070d","slug":"changes","fullItemName":"Changes"},{"id":"c386cd94-aafd-5fe3-8a55-e502f9f681d1","slug":"update","fullItemName":"Update"}]},{"id":"a7c1505d-66b8-52d6-9b36-239f3eadfed0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c0dae047-42fb-5e25-9862-8967f319e9ee","slug":"goals","fullItemName":"Goals"},{"id":"a4744067-6bed-5f73-8911-66c7ff78570c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"89cbccbf-01cf-5343-bfb7-bad7760a2ded","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8b5c3a47-9564-552f-83c2-64f8926bec29","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6cd42b4c-a956-560f-9c6c-a0e3521bbace","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9f22fed3-714e-5abe-9a52-34870887e267","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2ebe6cd7-4b6e-5541-9699-5f4e0af542fe","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b4bf3870-e41e-51aa-8ea8-ce962d1735b8","slug":"definition","fullItemName":"Definition"},{"id":"9aec8640-ee39-5d2f-97df-a62f06464af5","slug":"prevalence","fullItemName":"Prevalence"},{"id":"82e41ac8-9c05-5599-bdc6-d1ea0a1ecf7a","slug":"complications","fullItemName":"Complications"}]},{"id":"d1509154-ef5a-52ae-9c75-a9b6bf3bd4bf","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7159a76b-b760-5ee5-8e00-afc991a5ecb9","slug":"diagnosis-women","fullItemName":"Diagnosis - women"},{"id":"159b50a4-88fe-5cf2-9af2-43893eeeec84","slug":"diagnosis-men","fullItemName":"Diagnosis - men"}]},{"id":"004f5906-27c9-56f0-a599-802d0bdffa7c","fullItemName":"Management","slug":"management","subChapters":[{"id":"1c2af37c-700d-5c7c-95ea-049cde93a7e1","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b06121d3-a41a-5e65-a720-76900da7e5e7","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4c83875e-ed21-58f7-99f4-4a509deb53b5","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"cdff86f4-ac12-56d7-b196-c5f9af1eb880","slug":"tinidazole","fullItemName":"Tinidazole"}]},{"id":"9e19b288-e085-5577-8ad2-b0a504a27f7f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7ab5ef58-ff30-5498-8faa-115c4d60dd3f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"11960892-2762-52d0-8fac-3c436e4d4738","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a0cf5333-25ca-5bf8-9b3b-547067cd8d5f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d9ecf639-6f52-5f87-85be-f921ce43f237","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"24dfa3bf-b2cc-5ace-9f72-a47e822dd30a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7c7dfdd9-03c3-520f-a183-13ce32d19151","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c998f4ca-7088-5e78-95d0-67151407d497","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b06121d3-a41a-5e65-a720-76900da7e5e7","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"51c7f811-c955-5a92-83f9-7ebdd2cb4f85","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 27c755e0-582e-4b00-a5c0-0983e7efdabe --><h3>What are the contraindications and cautions for metronidazole?</h3><!-- end field 27c755e0-582e-4b00-a5c0-0983e7efdabe -->","summary":"","htmlStringContent":"<!-- begin item 984e00fb-bc2e-4dc4-849e-359c66feb0f0 --><!-- begin field 7f1f6f2c-b423-4aae-b253-05b46e979f19 --><ul><li><strong>Do not prescribe metronidazole to people with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li></ul></li><li><strong>Prescribe metronidazole with caution </strong><strong>to:</strong><ul><li>People with active or chronic severe peripheral and central nervous system disease — risk of neurological aggravation.</li><li>People with Cockayne syndrome — cases of severe hepatotoxicity/acute hepatic failure (including cases with a fatal outcome with very rapid onset after treatment initiation in people with Cockayne syndrome) have been reported with systemic metronidazole.<ul><li>Only prescribe metronidazole after careful benefit-risk assessment and only if no alternative treatment is available.</li><li>Perform liver function tests (LFTs) just prior to the start of treatment, during treatment, and at the end of treatment until liver function is within normal ranges, or until the baseline values are reached.</li><li>If the LFTs become markedly elevated during treatment with metronidazole, discontinue the treatment. </li><li>Advise the person to immediately report any symptoms of potential liver injury and to stop taking metronidazole if these occur.</li></ul></li><li>People with severe liver disease or hepatic encephalopathy — metronidazole is mainly metabolized by hepatic oxidation. Substantial impairment of metronidazole clearance may occur in the presence of advanced hepatic insufficiency. Significant cumulation may occur in people with hepatic encephalopathy, and the resulting high plasma concentrations of metronidazole may contribute to the symptoms of the encephalopathy. Prescribe one third of the <a class=\"topic-reference internal-reference\" href=\"/topics/trichomoniasis/management/management/#management\">recommended daily dose</a> once daily.</li><li>People with alcohol dependency — there may be a disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) if taken with alcohol.</li><li>Pregnant or breastfeeding women. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/trichomoniasis/prescribing-information/metronidazole/#pregnancy-breastfeeding\">Pregnancy and breastfeeding</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 7f1f6f2c-b423-4aae-b253-05b46e979f19 --><!-- end item 984e00fb-bc2e-4dc4-849e-359c66feb0f0 -->","subChapters":[]},{"id":"7ef04971-ad0b-51d5-9dc7-83010c99c9fd","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d1dcdab1-0c7c-468f-97fc-3911999237d9 --><h3>What are the adverse effects of metronidazole?</h3><!-- end field d1dcdab1-0c7c-468f-97fc-3911999237d9 -->","summary":"","htmlStringContent":"<!-- begin item 715700aa-3709-4db0-93b5-43e446d06472 --><!-- begin field 23ed35e8-fe9b-4c43-981b-f02e0a9450cc --><ul><li><strong>Severe bullous skin reactions, </strong>such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or acute generalized exanthematous pustulosis (AGEP), have been rarely reported with oral metronidazole. If symptoms/signs are present, treatment must be immediately discontinued.</li><li><strong>Other adverse effects of oral metronidazole include:</strong><ul><li><strong>Very rare</strong> — arthralgia, myalgia, ataxia, darkening of urine, dizziness, drowsiness, headache, pruritus, rash, erythema multiforme, hepatitis, jaundice, leucopenia (on prolonged or intensive therapy), pancytopenia, thrombocytopenia, pancreatitis, peripheral neuropathy (on prolonged or intensive treatment), psychotic disorders, transient epileptiform seizures (on prolonged or intensive treatment), and visual disturbances.</li><li><strong>Frequency not known</strong> — anorexia, aseptic meningitis, furred tongue, gastrointestinal disturbances, nausea, vomiting, oral mucositis, taste disturbances, and optic neuropathy.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 23ed35e8-fe9b-4c43-981b-f02e0a9450cc --><!-- end item 715700aa-3709-4db0-93b5-43e446d06472 -->","subChapters":[]},{"id":"d85cced9-7903-5fa0-a81a-168b29afccc2","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 5845a0a4-a43e-4e6a-8cfd-6e48a8961db3 --><h3>What are the drug interactions of metronidazole?</h3><!-- end field 5845a0a4-a43e-4e6a-8cfd-6e48a8961db3 -->","summary":"","htmlStringContent":"<!-- begin item 9233100e-9c09-4294-9f3c-0bd4459b9145 --><!-- begin field e7a42675-b4df-4092-9ac1-5e8a109f1b60 --><ul><li><strong>Drug interactions with oral metronidazole include:</strong><ul><li><strong>Alcohol</strong> — some people taking oral metronidazole experience a disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) with alcohol.<ul><li>Although there is no conclusive evidence to support this interaction, warn the person that they might experience this reaction if they drink alcohol whilst taking metronidazole.</li><li>Advise that alcohol should be avoided during treatment with metronidazole and for at least 48 hours afterwards.</li></ul></li><li><strong>Anticoagulants</strong> — the anticoagulant effects of warfarin and acenocoumarol can be markedly increased by metronidazole. There is no interaction with heparin. <ul><li>Monitor the international normalized ratio (INR) if concurrent treatment is indicated, and adjust the anticoagulant dose accordingly.</li><li>Warn the person of the possible risk of increased bruising and bleeding, and advise them on when to seek medical help.</li></ul></li><li><strong>Ciclosporin</strong> — people receiving concurrent metronidazole and ciclosporin are at risk of elevated serum ciclosporin levels.<ul><li>When co-administration of metronidazole and ciclosporin is necessary, monitor serum ciclosporin and creatinine levels closely.</li></ul></li><li><strong>Lithium</strong> — raised lithium levels accompanied by evidence of possible renal damage has been reported in people treated simultaneously with lithium and metronidazole.<ul><li>Before starting metronidazole in a person taking lithium, seek specialist advice about tapering or stopping lithium treatment.</li><li>If concurrent treatment is unavoidable, closely monitor plasma concentrations of lithium, creatinine, and electrolytes.</li></ul></li><li><strong>Phenobarbital or phenytoin</strong> — people receiving phenobarbital or phenytoin metabolize metronidazole at a much greater rate than normal, thereby reducing the half-life to approximately 3 hours. In addition, both metronidazole and phenytoin can increase the risk of peripheral neuropathy.</li></ul></li><li><strong>Oral hormonal contraceptives </strong>— additional contraceptive precautions are not required during or after courses of metronidazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete list of possible drug interactions of </strong><strong>metronidazole</strong><strong><strong>,</strong> </strong>see the <a data-hyperlink-id=\"5203f819-92f2-4ec0-b745-a94a00ee63e5\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"3eb72c95-6193-4a8b-81f0-a94a00ee64a5\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field e7a42675-b4df-4092-9ac1-5e8a109f1b60 --><!-- end item 9233100e-9c09-4294-9f3c-0bd4459b9145 -->","subChapters":[]},{"id":"ed043c66-e1b8-513f-b566-0fd0f6193efa","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 04eb20ee-6928-40bc-a664-c19500b6e0be --><h3>Pregnancy and breastfeeding</h3><!-- end field 04eb20ee-6928-40bc-a664-c19500b6e0be -->","summary":"","htmlStringContent":"<!-- begin item d176947c-2ae8-4069-bd86-80252ad04a1a --><!-- begin field 682ad96b-c97e-4414-9efc-34ee39555f52 --><ul><li><strong>Pregnancy</strong><ul><li>Although there is inadequate evidence of the safety of metronidazole in pregnancy, it has been in wide use for many years without clinical issues [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2019</a>]. </li><li>According to the United Kingdom Teratology Information Service (UKTIS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">UKTIS, 2017</a>]:<ul><li>Available data, which are almost exclusively based on oral exposure, do not indicate an increased risk of congenital malformation, low birth weight, intrauterine death, or neonatal complications with metronidazole use in human pregnancy.</li><li>Preterm delivery has been reported in women with bacterial vaginosis or trichomoniasis. However, the relative contribution of the underlying maternal infection and metronidazole exposure to pregnancy outcome is uncertain, and recent studies have not found an association between metronidazole use and preterm delivery.</li><li>Data on spontaneous abortion are conflicting: a cohort study found no significant increase in risk, whereas a nested case-control analysis suggests a possible association with metronidazole treatment in pregnancy.</li></ul></li><li>The manufacturer states that metronidazole should not be given during pregnancy unless essential and that short, high-dose treatment courses are not recommended during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2019</a>].</li></ul></li><li><strong>Breastfeeding</strong><ul><li>A significant amount of metronidazole enters breast milk and may give it a bitter taste [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Joint Formulary Committee, 2019</a>].</li><li>The manufacturer states that metronidazole should not be used during breastfeeding unless essential and that short, high-dose treatment courses are not recommended during breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2019</a>]. </li></ul></li></ul><!-- end field 682ad96b-c97e-4414-9efc-34ee39555f52 --><!-- end item d176947c-2ae8-4069-bd86-80252ad04a1a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}